4CPS-064

L01- ANTINEOPLASTIC AGENTS

EFFECTIVENESS OF RIBOCICLIB AND ABEMACICLIB AS FIRST LINE TREATMENT FOR METASTATIC BREAST CANCER IN POST-MENOPAUSAL WOMEN

M.D.P. BRICEÑO CASADO[1], M.D. GIL-SIERRA[2], C.M. CUADROS-MARTINEZ[1], B. DE LA CALLE-RIAGUAS[3], R. GAVIRA-MORENO[1].
[1]HOSPITAL UNIVERSITARIO DE JEREZ DE LA FRONTERA, HOSPITAL PHARMACY, JEREZ DE LA FRONTERA CÁDIZ, SPAIN. [2]HOSPITAL UNIVERSITARIO PUERTO REAL, HOSPITAL PHARMACY, PUERTO REAL, SPAIN. [3]HOSPITAL NUESTRA SEÑORA DEL PRADO, HOSPITAL PHARMACY, TALAVERA DE LA REINA, SPAIN.

BACKGROUND AND IMPORTANCE

- **Ribociclib** and **abemaciclib** → cyclin-dependent kinase 4/6 inhibitors (CDK4/6-i) used as treatment for patients with negative epidermal growth factor receptor 2 (**HER2-**) and positive hormone receptor (**HR+**) **metastatic breast cancer** (MBC).
- **MONALEESA-2** and **MONARCH-3** trials → evaluated the efficacy of this drugs as first line treatment in post-menopausal women.

AIM AND OBJECTIVES

To assess **effectiveness** of **ribociclib** and **abemaciclib** in HER2- and HR+ MBC in clinical practice, comparing results with reference bibliography.

MATERIAL AND METHODS

- Descriptive retrospective study.
- **Post-menopausal women** with **HER2-** and **HR+ MBC** receiving **CDK4/6-i** as **first line** of treatment between August-2017 and September-2022.
- Data recorded from electronic clinical history and prescription program Prisma®: gender, age, ECOG, CDK4/6-i and combined endocrine therapy, dosage and treatment duration.

EFFECTIVENESS → assessed by:

- progression free survival (PFS)
- overall survival (OS)
- PFS rate at 12 months

Using Kaplan-Meyer statistical analysis with SPSS V.21.0.

Results were compared with those described in pivotal clinical trials.

RESULTS

- 63 women included. Mean age = 63 (range 50-84) years.
- At baseline: ECOG=0/1 was observed in 93.7% cases and ECOG=2/3 in 6.3%.
- CDK4/6-i combined with letrozole in 58.7% patients and fulvestrant in 41.3%.

	RIBOCICLIB	ABEMACICLIB
% of patients	49.20%	50.80%
Dose reduction	48.4% patients	34.4% patients
Median treatment duration	16 (2-54) months	11 (2-32) months
Estimated PFS median	28.0 (95%CI: 6.6-49.3) months	Not reached
Estimated OS median	Not reached	Not reached
PFS rate at 12 months	67.3% (95%CI: 58.8-75.8)	60.7% (95%CI: 51.4-70.0)

	REFERENCE BIBLIOGRAPHY	
Trial	**MONALEESA-2**	**MONARCH-3**
Drug	Ribociclib	Abemaciclib
PFS median	25.3 months	28.2 months
OS median	63.9 months	Not reached
12-month PFS rate	72.80%	Not described

CONCLUSION AND RELEVANCE

Real-life effectiveness results confirmed a substantial benefit of ribociclib and abemaciclib. These data appeared to be slightly superior than those described in the literature. Larger sample size and longer follow-up time are necessary to extract more conclusive information.